Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Jan 19

PMID 29342918

Citations 22

Authors

Marta Moskot

Katarzyna Bochenska

Joanna Jakobkiewicz-Banecka

Bogdan Banecki

Magdalena Gabig-Ciminska

Affiliations

Soon will be listed here.

Abstract

Research in recent years has shown that sphingolipids are essential signalling molecules for the proper biological and structural functioning of cells. Long-term studies on the metabolism of sphingolipids have provided evidence for their role in the pathogenesis of a number of diseases. As many inflammatory diseases, such as lysosomal storage disorders and some dermatologic diseases, including psoriasis, atopic dermatitis and ichthyoses, are associated with the altered composition and metabolism of sphingolipids, more studies precisely determining the responsibilities of these compounds for disease states are required to develop novel pharmacological treatment opportunities. It is worth emphasizing that knowledge from the study of inflammatory metabolic diseases and especially the possibility of their treatment may lead to insight into related metabolic pathways, including those involved in the formation of the epidermal barrier and providing new approaches towards workable therapies.

Citing Articles

Normal and Dysregulated Sphingolipid Metabolism: Contributions to Podocyte Injury and Beyond.

Tolerico M, Merscher S, Fornoni A Cells. 2024; 13(11).

PMID: 38891023 PMC: 11171506. DOI: 10.3390/cells13110890.

Common genetic risk for Parkinson's disease and dysfunction of the endo-lysosomal system.

Bhore N, Bogacki E, OCallaghan B, Plun-Favreau H, Lewis P, Herbst S Philos Trans R Soc Lond B Biol Sci. 2024; 379(1899):20220517.

PMID: 38368938 PMC: 10874702. DOI: 10.1098/rstb.2022.0517.

Crosstalk between Serum and Skin Sphingolipids in Psoriasis.

Matwiejuk M, Mysliwiec H, Lukaszuk B, Lewoc M, Malla H, Mysliwiec P Int J Mol Sci. 2023; 24(19).

PMID: 37834321 PMC: 10573408. DOI: 10.3390/ijms241914872.

The Role of Sphingolipids and Sphingosine-1-phosphate-Sphingosine-1-phosphate-receptor Signaling in Psoriasis.

Masuda-Kuroki K, Alimohammadi S, Di Nardo A Cells. 2023; 12(19).

PMID: 37830566 PMC: 10571972. DOI: 10.3390/cells12192352.

Lipid Metabolism Disorder in Cerebrospinal Fluid Related to Parkinson's Disease.

Qiu J, Wei L, Su Y, Tang Y, Peng G, Wu Y Brain Sci. 2023; 13(8).

PMID: 37626522 PMC: 10452343. DOI: 10.3390/brainsci13081166.

References

Nijveldt R, van Nood E, van Hoorn D, Boelens P, van Norren K, Van Leeuwen P . Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001; 74(4):418-25. DOI: 10.1093/ajcn/74.4.418. View

Sandhoff K, Andreae U, JATZKEWITZ H . Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. Pathol Eur. 1968; 3(2):278-85. View

Ruvolo P, Clark W, Mumby M, Gao F, May W . A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem. 2002; 277(25):22847-52. DOI: 10.1074/jbc.M201830200. View

Merrill Jr A . Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev. 2011; 111(10):6387-422. PMC: 3191729. DOI: 10.1021/cr2002917. View

Zimran A, Zaizov R, Zlotogora J . [Large scale screening for Gaucher's disease in Israel--a position paper by the National Gaucher Committee of the Ministry of Health]. Harefuah. 1997; 133(3-4):107-8. View

Holland W, Summers S . Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008; 29(4):381-402. PMC: 2528849. DOI: 10.1210/er.2007-0025. View

Holleran W, Takagi Y, Uchida Y . Epidermal sphingolipids: metabolism, function, and roles in skin disorders. FEBS Lett. 2006; 580(23):5456-66. DOI: 10.1016/j.febslet.2006.08.039. View

Brunetti-Pierri N, Scaglia F . GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008; 94(4):391-396. DOI: 10.1016/j.ymgme.2008.04.012. View

Olivera A, Spiegel S . Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993; 365(6446):557-60. DOI: 10.1038/365557a0. View

10.

Sidransky E, Sherer D, Ginns E . Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr Res. 1992; 32(4):494-8. DOI: 10.1203/00006450-199210000-00023. View

11.

Gratchev A, Guillot P, Hakiy N, Politz O, Orfanos C, Schledzewski K . Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol. 2001; 53(4):386-92. DOI: 10.1046/j.1365-3083.2001.00885.x. View

12.

Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S . Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009; 24(7):2102-11. PMC: 2698092. DOI: 10.1093/ndt/gfp031. View

13.

Hojjati M, Li Z, Jiang X . Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. Biochim Biophys Acta. 2005; 1737(1):44-51. DOI: 10.1016/j.bbalip.2005.08.006. View

14.

Hannun Y, Loomis C, Merrill Jr A, Bell R . Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem. 1986; 261(27):12604-9. View

15.

Nakajima K, Terao M, Takaishi M, Kataoka S, Goto-Inoue N, Setou M . Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. J Invest Dermatol. 2013; 133(11):2555-2565. DOI: 10.1038/jid.2013.199. View

16.

Smith D, Wallom K, Williams I, Jeyakumar M, Platt F . Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis. 2009; 36(2):242-51. DOI: 10.1016/j.nbd.2009.07.010. View

17.

Garcia-Ruiz C, Colell A, Morales A, Calvo M, Enrich C, Fernandez-Checa J . Trafficking of ganglioside GD3 to mitochondria by tumor necrosis factor-alpha. J Biol Chem. 2002; 277(39):36443-8. DOI: 10.1074/jbc.M206021200. View

18.

Zhang Y, Yao B, Delikat S, Bayoumy S, Lin X, Basu S . Kinase suppressor of Ras is ceramide-activated protein kinase. Cell. 1997; 89(1):63-72. DOI: 10.1016/s0092-8674(00)80183-x. View

19.

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

20.

Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K . Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell. 1996; 86(2):209-19. DOI: 10.1016/s0092-8674(00)80093-8. View